1.62
-0.04(-2.41%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.66 |
| Day High | 1.66 |
| Day Low | 1.53 |
| 52-Week High | 8.08 |
| 52-Week Low | 1.17 |
| Volume | 307,534 |
| Average Volume | 557,905 |
| Market Cap | 35.43M |
| PE | -0.17 |
| EPS | -9.29 |
| Moving Average 50 Days | 1.82 |
| Moving Average 200 Days | 2.27 |
| Change | -0.04 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $9.18 as of February 12, 2026 at a share price of $1.62. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $1.67 as of February 12, 2026 at a share price of $1.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
GlobeNewswire Inc.
2 hours ago
Third party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 1
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
GlobeNewswire Inc.
Jan 20, 2026 12:00 PM GMT
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics